Regenerative Medicine Leader Michael H. May Joins AgeX Board of Directors
August 05 2019 - 5:14PM
Business Wire
Dr. May, CEO of Canada’s Centre for
Commercialization of Regenerative Medicine (CCRM), brings 20 years
of sector knowledge, leadership experience, and extensive global
industry and investor networks
AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a
biotechnology company focused on developing and commercializing
innovative therapeutics for human aging, announced today that
Michael H. May, Ph.D., has joined its Board of Directors. Dr. May
fills a recent vacancy on the Board for an independent member,
following the departure of Michael Mulroy, which was not because of
a disagreement with AgeX on any matter relating to company
operations, policies, or practices.
Dr. May is President and CEO of Canada’s Centre for
Commercialization of Regenerative Medicine (CCRM), a leading and
highly successful public-private partnership, which he has grown
from inception to over 100 experts, and which under his leadership
has raised over $100M, with spin-off companies and academic
partners supported by CCRM securing an additional $750M. Dr. May
has extensive experience serving on a diverse range of company
boards and industry-focused advisory committees, including at the
International Society for Cell Therapy (ISCT), the Alliance for
Regenerative Medicine (ARM), and the International Society for Stem
Cell Research (ISSCR). Dr. May holds a Ph.D. in Chemical
Engineering from the University of Toronto.
“We are pleased to welcome Dr. May to the Board of AgeX,” said
Greg Bailey, M.D., Chairperson of the Board of Directors of AgeX.
“Dr. May is a globally-recognized leader in regenerative medicine.
We believe Dr. May will play an invaluable role in unlocking the
commercial value of PureStem®, AgeX’s cell derivation and
manufacturing platform, and UniverCyte™, AgeX’s cell immune
tolerance platform, through global partnerships, while
simultaneously helping to progress our internal cell therapy
programs toward the clinic and commercialization.” Dr. Bailey
added, “All of us at AgeX would like to thank Michael Mulroy for
his invaluable service to AgeX during its formation and transition
to a public company, and we wish him all the best in future
endeavors.”
“AgeX has a number of transformative platform technologies
across the entire regenerative medicine space,” said Dr. May. “I am
delighted to be joining the Board at this exciting time, and I look
forward to contributing to the success of the company.”
About AgeX Therapeutics
AgeX Therapeutics, Inc. (NYSE American: AGE) is focused on
developing and commercializing innovative therapeutics for human
aging. Its PureStem® and UniverCyte™ manufacturing and
immunotolerance technologies are designed to work together to
generate highly defined, universal, allogeneic, off-the-shelf
pluripotent stem cell-derived young cells of any type for
application in a whole host of diseases with a high unmet medical
need. AgeX has two preclinical cell therapy programs: AGEX-VASC1
(vascular progenitor cells) for tissue ischemia and AGEX-BAT1
(brown fat cells) for Type II diabetes. AgeX’s revolutionary
longevity platform named induced Tissue Regeneration (iTR™) aims to
unlock cellular immortality and regenerative capacity to reverse
age-related changes within tissues. AGEX-iTR1547 is an iTR-based
formulation in preclinical development. HyStem® is AgeX’s delivery
technology to stably engraft PureStem cell therapies and slowly
release iTR molecules in the body. AgeX is developing its core
product pipeline for use in the clinic to extend human healthspan,
and is seeking opportunities to form licensing and partnership
agreements around its broad IP estate and proprietary technology
platforms for non-core clinical applications.
For more information, please visit www.agexinc.com or connect
with the company on Twitter, LinkedIn, Facebook, and YouTube.
Forward-Looking Statements
Certain statements contained in this release are
“forward-looking statements” within the meaning of the Private
Securities Litigation Reform Act of 1995. Any statements that are
not historical fact including, but not limited to statements that
contain words such as “will,” “believes,” “plans,” “anticipates,”
“expects,” “estimates” should also be considered forward-looking
statements. Forward-looking statements involve risks and
uncertainties. Actual results may differ materially from the
results anticipated in these forward-looking statements and as such
should be evaluated together with the many uncertainties that
affect the business of AgeX Therapeutics, Inc. and its
subsidiaries, particularly those mentioned in the cautionary
statements found in more detail in AgeX’s reports filed with the
Securities and Exchange Commissions (copies of which may be
obtained at www.sec.gov). Subsequent events and developments may
cause these forward-looking statements to change. AgeX specifically
disclaims any obligation or intention to update or revise these
forward-looking statements as a result of changed events or
circumstances that occur after the date of this release, except as
required by applicable law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190805005659/en/
for AgeX: Bill Douglass Gotham Communications, LLC
bill@gothamcomm.com (646) 504-0890
AgeX Therapeutics (AMEX:AGE)
Historical Stock Chart
From Mar 2024 to Apr 2024
AgeX Therapeutics (AMEX:AGE)
Historical Stock Chart
From Apr 2023 to Apr 2024